CellFE® and Syenex Collaborate to Advance Cell Engineering with Hybrid Gene Editing Workflow

ALAMEDA, Calif., Jan. 9, 2025 /PRNewswire/ -- CellFE^®, a leader in non-viral gene editing technology, and Syenex, a pioneer in enveloped delivery vectors, have announced an innovative collaboration to create a hybrid workflow that seamlessly integrates non-viral and viral approaches to cell therapy engineering. This next-generation process aims to enable streamlined workflows of complex edited cells for biotech and pharmaceutical applications. 

The collaboration application note will be officially unveiled the week of the highly anticipated J.P. Morgan Healthcare Conference in San Francisco this January, a premier event that brings together industry leaders, investors, and innovators from around the world.

"The market has been anticipating a solution that seamlessly integrates non-viral knockout with viral knockin capabilities into a streamlined workflow—one that preserves cell viability and functionality without compromise." said Dr. Alla Zamarayeva, CEO of CellFE. "By collaborating with Syenex, we are directly addressing this critical need."

Jay Rosanelli, CEO at Syenex, added: "This joint effort showcases the role of collaborative science in accelerating the creation of life-changing medicines for patients around the globe. We are thrilled to partner with CellFE and showcase the potential of this novel hybrid workflow to dramatically simplify manufacturing of genetic medicines."

This collaboration comes at a pivotal time as allogeneic and autologous cell therapy providers seek more efficient manufacturing processes. A key challenge is developing gentler yet highly effective techniques for delivering gene-editing cargo to patient cells, as current methods—often involving viral transduction and electroporation—can be detrimental to cells and extend recovery and processing times, particularly for complex, sequential editing. This innovative hybrid workflow aims to overcome these challenges, enabling advanced genetic editing while preserving cell functionality and supporting streamlined workflows.

Both companies will be attending the J.P. Morgan Healthcare Conference this month from January 13-16th. Details on where to partner with the companies at the conference can be found below, along with contact information for both companies.

Partner with CellFE at the JP Morgan Healthcare Conference:

• J.P. Morgan Healthcare Conference – Jan 13-16
  Westin St. Francis in San Francisco, CA

• Biotech Showcase – Jan 13-15
  Hilton Union Square, San Francisco, CA

• Bio Partnering at JPMorgan Week – Jan 13-16
  San Francisco Marriott Marquis in San Francisco, CA
  cellfebiotech.com/meet

Partner with Syenex at the JP Morgan Healthcare Conference:

• Bio Partnering at JPMorgan Week – Jan 13-16
  San Francisco Marriott Marquis in San Francisco, CA
  syenex.com/meet

About CellFE Biotech
CellFE, a cutting-edge microfluidics company, is transforming the development and manufacturing of lifesaving cell therapies to make them more accessible to patients. CellFE aims to unlock the full potential of this transformative modality by tackling its key market challenges, notably high manufacturing costs and extended vein-to-vein timelines. With a focus on T-Cell, HSC, and iPSC-based therapies, CellFE's microfluidics-based gene-delivery technology, in conjunction with proprietary best-in-class workflows, targets critical bottlenecks in cell therapy manufacturing. For more information, please visit www.cellfebiotech.com.

About Syenex
Syenex builds bioengineering technologies to unlock the future of human health. Leveraging the power of synthetic biology, we design scalable, precision-engineered gene delivery vectors, empowering cell and gene therapy developers to cure disease and build the next generation of medicines. Designed to break the barriers that slow medical progress, our Open Science model ensures global access to our expanding toolkit and a network of scale-up partners, accelerating the path of breakthroughs from idea to impact for all of academia and biopharma. Since 2022, Syenex has rapidly built a portfolio of cell-specific bioengineering systems and established partnerships across the fields of immune cell, stem cell, and hepatocyte engineering. Learn more and get started at www.syenex.com.

SOURCE CellFE